Related Experiment Video
Updated: Dec 10, 2025

Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease
Published on: June 16, 2023
Prescribed Walking for Glycemic Control and Symptom Management in Patients Without Diabetes Undergoing Chemotherapy
Marilyn J Hammer1, Patricia Eckardt, Frances Cartwright
1Marilyn J. Hammer, PhD, DC, RN, FAAN, is the Director, Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, and Member of the Faculty, Medical Oncology, Harvard Medical School, Boston, Massachusetts. Patricia Eckardt, PhD, RN, FAAN, is Professor, Barbara H. Hagan School of Nursing and Health Sciences, Molloy College, Rockville Center, New York. Frances Cartwright, PhD, RN, AOCN, FAAN, is the Chief Nursing Officer and Senior Vice President, Department of Nursing, The Mount Sinai Hospital, and Associate Professor, Icahn School of Medicine at Mount Sinai, New York, New York. Christine Miaskowski, PhD, RN, FAAN, is Professor and Vice Chair for Research, Sharon Lamb Endowed Chair in Symptom Management Research, and American Cancer Society Clinical Research Professor, University of California, San Francisco.
Background:
Hyperglycemia may potentiate symptom experiences. Exercise is a nonpharmacological intervention that can potentially improve glycemic control and mitigate symptom experiences in patients undergoing chemotherapy for cancer.
Objectives:
The primary objective was to assess the feasibility of patients engaging in a walking exercise study for 6 months. We also evaluated the effects of a prescribed walking program on glycemic control and for changes over time in the severity of pain, fatigue, depression, and sleep disturbance in patients undergoing chemotherapy for breast, lung, gynecologic, or gastrointestinal cancer.
Methods:
A randomized pilot intervention study was conducted to evaluate differences within and between a prescribed walking program intervention group and a control group. All patients were followed for 6 months, had glycosylated hemoglobin A1c measured at enrollment and 6 months, and completed symptom questionnaires at enrollment, 3 months, and 6 months. Data were analyzed using descriptive statistics and analysis of covariance.
Results:
Most of the patients who enrolled completed the 6-month study. The few who withdrew expressed feeling overwhelmed. The sample was predominately non-Hispanic White female patients with breast cancer with a normal-to-slightly-overweight body mass index. The intervention group had a slight decrease in glycosylated hemoglobin A1c at 6 months. In addition, at 6 months, compared to the control group, the intervention group had significantly less sleep disturbance and depression. No other within- or between-group differences were found.
Discussion:
It is feasible for patients undergoing chemotherapy to participate in a prescribed walking program. Exercise, such as walking, may decrease hyperglycemia and symptom severity. Additional research with larger samples is warranted.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes: Symptoms, Diagnosis, and Complications
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...

